MedPath

A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01

Phase 2
Terminated
Conditions
Rheumatoid Arthritis
Interventions
Registration Number
NCT00583557
Lead Sponsor
Human Genome Sciences Inc.
Brief Summary

This is a continuation trial of LymphoStat-B™ to evaluate the long-term safety in subjects with Rheumatoid Arthritis that completed study LBRA01 and benefitted from treatment.

Detailed Description

This is a multi-center, open label, continuation trial of LymphoStat-B™ in Rheumatoid Arthritis (RA) subjects who achieved at least an ACR20 response in the Phase 2 study LBRA01 (NCT00071812).

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
155
Inclusion Criteria
  1. Have completed the LBRA01 trial.
  2. Have achieved at least an ACR20 response at the end of LBRA01.

Primary

Read More
Exclusion Criteria
  1. Have switched NSAIDs due to worsening RA disease activity, used more than 10 mg/day of oral prednisone, or were given a corticosteroid injection during the last 30 days of LBRA01.

  2. Required a new DMARD (not otherwise excluded in protocol LBRA01) to replace an ineffective one, or an additional DMARD (not to exceed 2 DMARDs in total) within the last 60 days of LBRA01.

  3. Used prohibited medications during their participation in LBRA01. These medications include the following:

    • Other investigational agents.
    • Biologic response modifiers
    • Cyclophosphamide.
    • Corticosteroid injections (except 1 injection of up to 40 mg of prednisone into an inflamed joint or intramuscularly every 6 months).
    • 2 new DMARDs.
    • 1 new DMARD plus high dose prednisone >10 mg/day.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Belimumabbelimumab-
Primary Outcome Measures
NameTimeMethod
To Evaluate the Long-term Safety of LymphoStat-B™ in Subjects With RA.Up to 5 years

SEE ALSO ADVERSE EVENT (AE) RESULTS SECTION.

Secondary Outcome Measures
NameTimeMethod
The Efficacy Endpoints Will Include Long-term ACR Responses, DAS28 Response, C-reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), and Rheumatoid Factor (RF).up to 5 Years

NOT ANALYZED

Trial Locations

Locations (48)

University of Pittsburgh School of Medicine & ASPH

🇺🇸

Pittsburgh, Pennsylvania, United States

Wallace Rheumatic Disease Center

🇺🇸

Los Angeles, California, United States

IPC Clinical Research

🇺🇸

Ogden, Utah, United States

Rheumatic Disease Center

🇺🇸

Glendale, Wisconsin, United States

University of Southern CA

🇺🇸

Los Angeles, California, United States

Texas Research Center

🇺🇸

Sugar Land, Texas, United States

Marshfield Medical Research Foundation

🇺🇸

Wausau, Wisconsin, United States

Arthritis Clinic and Carolina Bone and Joint

🇺🇸

Charlotte, North Carolina, United States

Seattle Arthritis Clinic

🇺🇸

Seattle, Washington, United States

Arthritis Associates & Osteoporosis Center of Colorado Springs

🇺🇸

Colorado Springs, Colorado, United States

Univ of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

Arizona Arthritis Research

🇺🇸

Paradise Valley, Arizona, United States

Arthritis Health

🇺🇸

Scottsdale, Arizona, United States

The University of Arizona Health Sciences Center

🇺🇸

Tucson, Arizona, United States

Arthritis Care Center, Inc.

🇺🇸

San Jose, California, United States

Boling Clinical Trials

🇺🇸

Rancho Cucamonga, California, United States

Washington Hospital Center

🇺🇸

Washington, DC, District of Columbia, United States

Rheumatology Associates of Central Florida

🇺🇸

Orlando, Florida, United States

Arthritis and Rheumatic Disease Specialties

🇺🇸

Aventura, Florida, United States

Tampa Medical Group, P.A.

🇺🇸

Tampa, Florida, United States

Radiant Research Boise

🇺🇸

Boise, Idaho, United States

Rheumatology Associates

🇺🇸

Chicago, Illinois, United States

The Osteoporosis and Arthritis Clinical Trial Center

🇺🇸

Cumberland, Maryland, United States

Mayo Clinic

🇺🇸

Rochester, Minnesota, United States

Medical Specialists

🇺🇸

Munster, Indiana, United States

Kentuckiana Center for Better Bone and Joint Health

🇺🇸

Louisville, Kentucky, United States

Center for Rheumatology and Bone Research

🇺🇸

Wheaton, Maryland, United States

Washington University in St. Louis

🇺🇸

St. Louis, Missouri, United States

Arthritis Center of Nebraska

🇺🇸

Lincoln, Nebraska, United States

Strafford Medical Associates, P.A.

🇺🇸

Dover, New Hampshire, United States

The Center for Rheumatology

🇺🇸

Albany, New York, United States

North Shore University Hospital

🇺🇸

Manhasset, New York, United States

Bone and Joint Hospital - Research Department

🇺🇸

Oklahoma City, Oklahoma, United States

Wake Forest Unviersity School of Medicine

🇺🇸

Winston-Salem, North Carolina, United States

Oklahoma Medical Reseach Foundation

🇺🇸

Oklahoma City, Oklahoma, United States

Oklahoma Center for Arthritis Therapy & Research

🇺🇸

Tulsa, Oklahoma, United States

Rheumatic Disease Associates

🇺🇸

Willow Grove, Pennsylvania, United States

Arthritis Centers of Texas

🇺🇸

Dallas, Texas, United States

UT Southwestern Medical Center at Dallas

🇺🇸

Dallas, Texas, United States

Houston Institute for Clinical Research

🇺🇸

Houston, Texas, United States

Arthritis Clinic of Northern Virginia, P.C.

🇺🇸

Arlington, Virginia, United States

Arthritis Northwest Rheumatology

🇺🇸

Spokane, Washington, United States

Rheumatology Northwest Clinical Trials

🇺🇸

Yakima, Washington, United States

Gundersen Clinic, LTD

🇺🇸

La Crosse, Wisconsin, United States

NZOZ Centrum Medyczne

🇵🇱

Bialystok, Poland

Wojewodzki Zespol Reumatologiczny

🇵🇱

Sopot, Poland

Instytut Reumaologii

🇵🇱

Warszawa, Poland

Instytut Reumatologii

🇵🇱

Warszawa, Poland

© Copyright 2025. All Rights Reserved by MedPath